Connecting the Dots: GLP-1s, Psoriasis, and Total Spend

Here’s some total cost of care math for a Monday. Biologics for psoriasis average roughly $20,000–$40,000 per year. GLP-1 receptor agonists average $12,000–$16,000 per year. If improved weight control from GLP-1 RAs reduces psoriasis severity and allows some members to avoid or delay biologic therapy, employers could see meaningful net savings. Depending on drug prices, that difference can range from approximately $4,000 to $28,000 per member per year. Evidence supports this connection. Weight-loss interventions are associated with significant reductions in psoriasis severity and meaningful improvements in quality of life (Morrow et al., 2025). When we focus on whole-person care rather than isolated conditions or benefit categories, we uncover opportunities to improve outcomes and lower total cost of care. Quality, integrated care saves real dollars.

Morrow, S., Hawkins, P., Griffiths, C. E. M., Tektonidis, T. G., Harriss, E., Scragg, J., & Jebb, S. (2025). Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70247